NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 121 filers reported holding NURIX THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $365,176 | -69.9% | 46,460 | -61.7% | 0.00% | – |
| Q2 2023 | $1,213,385 | +276.4% | 121,460 | +234.6% | 0.00% | – |
| Q1 2023 | $322,344 | -82.0% | 36,300 | -77.7% | 0.00% | -100.0% |
| Q4 2022 | $1,788,642 | +65.6% | 162,900 | +96.5% | 0.00% | 0.0% |
| Q3 2022 | $1,080,000 | +16.4% | 82,900 | +13.2% | 0.00% | – |
| Q2 2022 | $928,000 | +101.3% | 73,261 | +122.7% | 0.00% | – |
| Q1 2022 | $461,000 | -51.5% | 32,900 | +0.3% | 0.00% | – |
| Q4 2021 | $950,000 | -65.7% | 32,800 | -64.5% | 0.00% | -100.0% |
| Q3 2021 | $2,772,000 | +218.6% | 92,524 | +182.1% | 0.00% | – |
| Q2 2021 | $870,000 | – | 32,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $18,210,601 | 1.88% |
| DAFNA Capital Management LLC | 556,695 | $5,561,383 | 1.52% |
| Deep Track Capital, LP | 2,997,830 | $29,948,322 | 1.39% |
| Redmile Group, LLC | 2,857,309 | $28,544,517 | 1.10% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,830,497 | 0.80% |
| Boxer Capital, LLC | 1,224,892 | $12,237 | 0.57% |
| AtonRa Partners | 30,142 | $301,119 | 0.47% |
| Affinity Asset Advisors, LLC | 100,000 | $999,000 | 0.35% |
| HARVARD MANAGEMENT CO INC | 314,762 | $3,144 | 0.31% |
| WASATCH ADVISORS LP | 3,869,775 | $38,659,052 | 0.23% |